ALDER BIOPHARMACEUTICALS INC's ticker is ALDR and the CUSIP is 014339105. A total of 142 filers reported holding ALDER BIOPHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 4.39 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $3,697,000 | -83.6% | 291,120 | -85.2% | 0.01% | -84.5% |
| Q4 2017 | $22,505,000 | +11.3% | 1,965,471 | +19.1% | 0.06% | +1.8% |
| Q3 2017 | $20,219,000 | +106.4% | 1,650,540 | +159.4% | 0.06% | +90.0% |
| Q2 2017 | $9,798,000 | -23.0% | 636,250 | +4.0% | 0.03% | -26.8% |
| Q1 2017 | $12,724,000 | +69.7% | 611,706 | +69.7% | 0.04% | +46.4% |
| Q4 2016 | $7,498,000 | +18.8% | 360,457 | +87.1% | 0.03% | +16.7% |
| Q3 2016 | $6,313,000 | -51.5% | 192,636 | -55.5% | 0.02% | -52.9% |
| Q2 2016 | $13,022,000 | +759.5% | 433,054 | +442.7% | 0.05% | +628.6% |
| Q1 2016 | $1,515,000 | -24.1% | 79,800 | +32.1% | 0.01% | -12.5% |
| Q4 2015 | $1,995,000 | +31.2% | 60,400 | +30.2% | 0.01% | +14.3% |
| Q3 2015 | $1,520,000 | -25.7% | 46,400 | +5.2% | 0.01% | -12.5% |
| Q2 2015 | $2,047,000 | +28.0% | 44,100 | -29.7% | 0.01% | +14.3% |
| Q1 2015 | $1,599,000 | – | 62,700 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 2,942,203 | $36,042,000 | 9.93% |
| Foresite Capital Management II, LLC | 1,043,832 | $12,787,000 | 5.18% |
| Redmile Group, LLC | 6,476,766 | $79,340,000 | 3.91% |
| DAFNA Capital Management LLC | 346,013 | $4,239,000 | 2.63% |
| Cormorant Asset Management, LP | 900,000 | $11,025,000 | 1.95% |
| SENZAR ASSET MANAGEMENT, LLC | 641,170 | $7,854,000 | 1.92% |
| Asymmetry Capital Management, L.P. | 105,228 | $1,289,000 | 1.50% |
| New Leaf Venture Partners, L.L.C. | 171,364 | $2,099,000 | 0.97% |
| EMERALD ADVISERS, LLC | 1,578,477 | $19,336,000 | 0.79% |
| BB BIOTECH AG | 2,266,008 | $27,759,000 | 0.77% |